Top Markets
#1 Gama Token Gama Token +9.13%
#2 Casper Network Casper Network +6.29%
#3 Berachain Berachain +4.11%
#4 Perle Perle +4.10%
#5 Cross Cross +3.98%
#6 Holoworld Holoworld +3.25%
#7 Venom Venom +3.12%
#8 Tutorial Tutorial +3.07%
#9 The Innovation Game The Innovation Game +3.01%
#10 Velvet Velvet +2.84%
Coin of the day
Gama Token Gama Token
Settings
Language
ENGLISH
Currency
USD
Theme
Apexigen, Inc. Apexigen, Inc.

Apexigen, Inc.

APGN
Rank in Stocks #36265
Apexigen Inc., established in 2010 and based in San Carlos, California, is a... Apexigen Inc., established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates. A primary focus is APX005M, a humanized agonist antibody currently in Phase II clinical trials. This therapeutic agent is being explored for its efficacy against a variety of solid tumors, including melanoma, esophageal and gastroesophageal junction cancers, sarcoma, and rectal and ovarian malignancies, often in conjunction with other established treatments like immunotherapy, chemotherapy, radiation therapy, and cancer vaccines. Additionally, Apexigen is progressing APX601, a humanized antagonist antibody, through Phase I/II clinical trials for numerous tumor indications. Rounding out their experimental portfolio is APX801, an NK cell engager engineered to stimulate natural killer cells to eradicate cancerous cells.
Share Price
$0.385
Last synced: 2023-09-01
Market Cap
$2.86M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Apexigen, Inc. (APGN)

Category

Healthcare
P/E ratio for Apexigen, Inc. (APGN)
P/E ratio as of 2026 TTM: 0
According to Apexigen, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Apexigen, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.